The tweet was deleted by the author.
But we saved everything 🙂.
Upstream Bio Inc. has named Marie Sanchirico, PhD, MBA, as head of Medical Affairs in a move designed to enhance its engagement with physicians and scientific experts.
Sanchirico will be instrumental in advancing initiatives that aim to improve care for patients affected by severe inflammatory respiratory diseases. Her appointment signals the company’s commitment to building deeper collaborations with key stakeholders in the medical community.
View post on X Loading...
Upstream Bio recently posted its second quarter 2026 results and announced trial updates, with its stock rising 2.6% to $7.44 following the news on the day of the release. The company is also planning to start Phase 3 trials for severe asthma and CRSwNP in early 2027 according to its announced timeline. These developments follow a period of expanded pipeline activity.